54346-35-9

Usage

Uses

Used in Pharmaceutical Research and Development:
8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol is used as a research compound for exploring its potential biological activities and therapeutic applications. Its unique structure and properties make it a valuable tool in the development of new drugs and medicinal compounds.
Used in Drug Discovery:
8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol is utilized as a lead compound in drug discovery processes. Its chemical properties and structural features can be further modified and optimized to enhance its therapeutic potential and target specific biological pathways.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol serves as a starting point for the synthesis of novel compounds with potential therapeutic benefits. Its versatile structure allows for various chemical modifications to improve its pharmacological properties and selectivity.
It is important to handle 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol with care due to potential hazards associated with its properties. Proper safety measures should be taken during its synthesis, storage, and use to minimize risks.

InChI:InChI=1/C6H5BrN4OS/c1-13-5-9-4-3(7)2-8-11(4)6(12)10-5/h2H,1H3,(H,9,10,12)

Upstream product

• 34683-00-6 ethyl N-[(1H-pyrazol-5-yl)carbamothioyl]carbamate 
• 34682-99-0 2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one 
• 54346-18-8 2-(methylsulfanyl)-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
• 948575-60-8 1,3-dihydro-8-bromopyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 
• 74-88-4 methyl iodide 
• 948575-57-3 C₇H₉BrN₄O₂S 
• 34682-99-0 2-sulfanylpyrazolo[1,5-a][1,3,5]triazin-4-ol 
• 948575-60-8 C₅H₃BrN₄SO 
• 54346-18-8 2-(methylsulfanyl)pyrazolo[1,5-a][1,3,5]triazin-4-ol 

Downstream Products

• 54346-33-7 8-bromo-2-(methylthio)-4-chloropyrazolo<1,5-a>-1,3,5-triazine 

Relevant academic research and scientific papers

PYRAZOLOTRIAZINES

The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

IMIDAZOTRIAZINES ACTING ON CANCER VIA INHIBITION OF CDK12

The present invention provides compounds of general formula (I): in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12

The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

Microwave-assisted sequential one-pot synthesis of 8-substituted pyrazolo[1,5-a][1,3,5]triazines

This paper reports a convenient sequential one-pot approach for the synthesis of an array of 14 pyrazolo[1,5-a][1,3,5]triazines, substituted in C8 by halogen (Br), various functions (CN and CO2Et)2 and alkyl or (het)aryl groups. This study conf

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

PYRAZOLO (1,5A) 1,3,5-TRIAZINES

Pyrazolo[1,5a]1,3,5-triazines are disclosed which are useful as inhibitors of phosphodiesterase enzymes or intermediate in the production process. Such triazines are of general structure: wherein R1, R2 and R3 are as defined hereinafter, or heterocyclic derivatives thereof. Also disclosed are substituted pyrazole derivatives which are used to prepare the pyrazolo[1,5a]1,3,5-triazines of this invention